摘要
目的:探讨参麦注射液对慢性肺心病心力衰竭患者血浆BNP、NT-proBNP的影响。方法:将86例慢性肺心病心力衰竭患者随机分为治疗组和对照组各43例,对照组采用常规治疗,治疗组在常规治疗基础上加用参麦注射液,疗程2周。测定治疗前后血浆BNP、NT-proBNP浓度。结果:治疗后两组血浆BNP、NT-proBNP水平较治疗前均有明显下降,而治疗组与对照组比较,治疗后血浆BNP、NT-proBNP水平较治疗前均下降更显著,差异有统计学意义(P<0.01);治疗2周后,两组患者的EF、△D%、△T%、Emax、Emax/Amax均有增加,与对照组相比,治疗组增加更为显著,差异有统计学意义(P<0.01);而两组治疗后比较差异有统计学意义(P<0.01)。结论:参麦注射液能提高左室收缩功能,并可降低血浆BNP及NT-proBNP水平,且不良反应小,是治疗慢性肺心病心力衰竭的有效辅助药物,值得在临床推广。
Objective:To explore the effect of Shenmai injection on the plasma BNP,NT-proBNP of patients with chronic pulmonary heart disease heart failure.Methods:86 cases with chronic pulmonary heart disease heart failure were randomly divided into the treatment group and the control group with 43 cases in each.The control group were treated with conventional treatment.The treatment group were treated with Shenmai injection on the basis of conventional treatment.The course of treatment was 2weeks.The plasma BNP,NT-proBNP concentration were measured before and after the treatment.Results:After the treatment,the plasma BNP,NT-proBNP levels of the two groups were significantly decreased than those before treatment. Compared with the control group, the plasma BNP,NT-proBNP levels of the treatment group after treatment were more significantly decreased than those before treatment(P<0.01).After 2 weeks of the treatment,EF, △ D%, △ T%,Emax,Emax/Amax of the two groups were increased.Compared with the control group,the treatment group were more significantly increased(P<0.01).The two groups after treatment were significantly different(P<0.01).Conclusion:Shenmai injection can improve the left ventricular systolic function,and reduce the plasma BNP and NT-proBNP levels.It has less adverse reactions.It is an effective adjunctive medicine in the treatment of chronic pulmonary heart disease heart failure.It is worth in clinical promotion.
关键词
肺心病
心力衰竭
参麦注射液
脑利钠肽
末端脑钠肽前体
Pulmonary heart disease
Heart failure
Shenmai injection
Brain natriuretic peptide
Pro-brain natriuretic peptide
